Novo resumes Wegovy 1.7 mg supply; GSK’s £200M manufacturing expansion in the UK; SmartLabs’ $48M Series Cnews2024-01-18T17:04:29+00:00January 18th, 2024|Endpoints News|
Lutetium, actinium or lead: Can isotope type offer an edge in radiotherapy?news2024-01-18T17:00:57+00:00January 18th, 2024|Endpoints News|
BridgeBio raises up to $1.2B, a month after submitting cardio drug to FDAnews2024-01-18T16:27:07+00:00January 18th, 2024|Endpoints News|
Viridian’s $150M offering; Surrozen scraps IBD drug candidate; Assembly ends deal with Indiana Universitynews2024-01-18T16:03:20+00:00January 18th, 2024|Endpoints News|
Bora Pharma to pay up to $210M for Upsher-Smith to expand into the USnews2024-01-18T13:36:11+00:00January 18th, 2024|Endpoints News|
CG Oncology aims for $181M listing in first biotech IPO of 2024news2024-01-18T12:18:36+00:00January 18th, 2024|Endpoints News|
Updated: Novartis ends PhIII peanut allergy trial for ligelizumab, expects new study later this yearnews2024-01-18T12:07:29+00:00January 18th, 2024|Endpoints News|
Satsuma’s nasal migraine candidate rejected by FDA over CMC issues news2024-01-18T11:22:26+00:00January 18th, 2024|Endpoints News|
Investment firm Mirae launches its US biotech VC fund with $50Mnews2024-01-18T11:00:25+00:00January 18th, 2024|Endpoints News|
Bayer to make significant cuts, rolls out new model at ‘expense of many managerial employees’news2024-01-17T20:52:42+00:00January 17th, 2024|Endpoints News|
